Ontology highlight
ABSTRACT: Objectives
To explore that if mid-regional sequence of pro-A-type natriuretic peptide (MR-proANP) may have a good value of diagnosis in heart failure with preserved ejection fraction (HFpEF) compared with N-terminal pro-B-type natriuretic peptide (NT-proBNP).Methods
Participants with cardiovascular disease who were enrolled in this study were divided into the nonheart failure (non-HF) group (n?=?75), HFpEF group (n?=?65), and HF with reduced ejection fraction (HFrEF) group (n?=?50). The MR-proANP and NT-proBNP levels in plasma from all patients were measured by enzyme-linked immunosorbent assay.Results
The plasma levels of MR-proANP and NT-proBNP in HFpEF and HFrEF groups were higher than those in non-HF group (P?ConclusionResults indicated that MR-proANP may be more sensitive and specific than NT-proBNP in diagnosing HFpEF. It may be used as a potential diagnostic biomarker in patients with HFpEF.
SUBMITTER: Cui K
PROVIDER: S-EPMC6133645 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Cui Kun K Huang Wei W Fan Jinqi J Lei Han H
Medicine 20180901 36
<h4>Objectives</h4>To explore that if mid-regional sequence of pro-A-type natriuretic peptide (MR-proANP) may have a good value of diagnosis in heart failure with preserved ejection fraction (HFpEF) compared with N-terminal pro-B-type natriuretic peptide (NT-proBNP).<h4>Methods</h4>Participants with cardiovascular disease who were enrolled in this study were divided into the nonheart failure (non-HF) group (n = 75), HFpEF group (n = 65), and HF with reduced ejection fraction (HFrEF) group (n = 5 ...[more]